Have a feature idea you'd love to see implemented?
Let us know!
ACLX Arcellx Inc
Price (delayed)
$86
Market cap
$4.62B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.04
Enterprise value
$4.6B
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which
Highlights
The EPS has surged by 74% year-on-year
Arcellx's quick ratio has soared by 70% YoY and by 10% from the previous quarter
Arcellx's net income has soared by 71% YoY but it has decreased by 7% from the previous quarter
Key stats
What are the main financial stats of ACLX
Market
Valuations
Earnings
Shares outstanding
53.76M
Market cap
$4.62B
Enterprise value
$4.6B
Price to earnings (P/E)
N/A
Price to book (P/B)
9.44
Price to sales (P/S)
31.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
31.76
Revenue
$144.75M
EBIT
-$50.09M
EBITDA
-$24.88M
Free cash flow
-$42.88M
Per share
Balance sheet
Liquidity
EPS
-$1.04
Free cash flow per share
-$0.8
Book value per share
$9.11
Revenue per share
$2.7
TBVPS
$13.72
Total assets
$734.31M
Total liabilities
$247.14M
Debt
$74.29M
Equity
$487.16M
Working capital
$441.91M
Debt to equity
0.15
Current ratio
6.01
Quick ratio
5.85
Net debt/EBITDA
1.04
Margins
Efficiency
Dividend
EBITDA margin
-17.2%
Gross margin
100%
Net margin
-37.2%
Operating margin
-55.7%
Return on assets
-7.3%
Return on equity
-12.4%
Return on invested capital
-9.8%
Return on capital employed
-7.8%
Return on sales
-34.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ACLX stock price
How has the Arcellx stock price performed over time
Intraday
-1.43%
1 week
-2.48%
1 month
2.98%
1 year
151.9%
YTD
54.95%
QTD
2.98%
Financial performance
How have Arcellx's revenue and profit performed over time
Revenue
$144.75M
Gross profit
$144.75M
Operating income
-$80.67M
Net income
-$53.89M
Gross margin
100%
Net margin
-37.2%
Arcellx's net margin has soared by 93% YoY and by 3.1% from the previous quarter
Arcellx's operating margin has soared by 91% YoY and by 2.5% from the previous quarter
Arcellx's net income has soared by 71% YoY but it has decreased by 7% from the previous quarter
The company's operating income has surged by 58% YoY but it fell by 7% QoQ
Growth
What is Arcellx's growth rate over time
Valuation
What is Arcellx stock price valuation
P/E
N/A
P/B
9.44
P/S
31.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
31.76
The EPS has surged by 74% year-on-year
The equity has surged by 66% year-on-year
ACLX's price to book (P/B) is 50% higher than its last 4 quarters average of 6.4
The price to sales (P/S) is 18% higher than the last 4 quarters average of 27.3
The company's revenue rose by 10% QoQ
Efficiency
How efficient is Arcellx business performance
The return on sales has surged by 94% year-on-year and by 2.5% since the previous quarter
ACLX's return on invested capital has surged by 85% year-on-year and by 12% since the previous quarter
The company's return on equity has surged by 82% YoY and by 5% QoQ
Arcellx's return on assets has surged by 81% YoY but it has decreased by 2.8% QoQ
Dividends
What is ACLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ACLX.
Financial health
How did Arcellx financials performed over time
ACLX's total assets is 197% higher than its total liabilities
Arcellx's quick ratio has soared by 70% YoY and by 10% from the previous quarter
Arcellx's current ratio has surged by 68% YoY and by 10% QoQ
Arcellx's debt is 85% less than its equity
The equity has surged by 66% year-on-year
ACLX's debt to equity has dropped by 53% year-on-year and by 17% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.